Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1980 Nov;66(5):1020–1032. doi: 10.1172/JCI109930

Evaluation of a Role for 1,25-Dihydroxyvitamin D3 in the Pathogenesis and Treatment of X-linked Hypophosphatemic Rickets and Osteomalacia

Marc K Drezner 1,2,3,4, Kenneth W Lyles 1,2,3,4, Mark R Haussler 1,2,3,4, John M Harrelson 1,2,3,4
PMCID: PMC371539  PMID: 6253520

Abstract

Although a defect in renal transport of phosphate seems well established as the primary abnormality underlying the pathogenesis of X-linked hypophosphatemic rickets and osteomalacia, several observations indicate that renal phosphate wasting and hypophosphatemia cannot solely account for the spectrum of abnormalities characteristic of this disease. Thus, in the present study, we investigated the potential role of abnormal vitamin D metabolism in the pathogenesis of this disorder and the effect of 1,25-dihydroxyvitamin D3 therapy on both the biochemical abnormalities characteristic of this disease and the osteomalacia. Four untreated patients, ages 14-30 yr, had normocalcemia (9.22±0.06 mg/dl); hypophosphatemia (2.25±0.11 mg/dl); a decreased renal tubular maximum for the reabsorption of phosphate per liter of glomerular filtrate (2.12±0.09 mg/dl); normal serum immunoreactive parathyroid hormone concentration; negative phosphate balance; and bone biopsy evidence of osteomalacia. The serum 25-hydroxyvitamin D3 concentration was 33.9±7.2 ng/ml and, despite hypophosphatemia, the serum level of 1,25-dihydroxyvitamin D3 was not increased, but was normal at 30.3±2.8 pg/ml. These data suggested that abnormal homeostasis of vitamin D metabolism might be a second defect central to the phenotypic expression of X-linked hypophosphatemic rickets/osteomalacia. This hypothesis was supported by evaluation of the long-term response to pharmacological amounts of 1,25-dihydroxyvitamin D3 therapy in three subjects. The treatment regimen resulted in elevation of the serum 1,25-dihydroxyvitamin D levels to values in the supraphysiological range. Moreover, the serum phosphate and renal tubular maximum for the reabsorption of phosphate per liter of glomerular filtrate increased towards normal whereas the phosphate balance became markedly positive. Most importantly, however, repeat bone biopsies revealed that therapy had positively affected the osteomalacic component of the disease, resulting in normalization of the mineralization front activity. Indeed, a central role for 1,25-dihydroxyvitamin D3 in the mineralization of the osteomalacic bone is suggested by the linear relationship between the serum level of this active vitamin D metabolite and the mineralization front activity. We, therefore, suggest that a relative deficiency of 1,25-dihydroxyvitamin D3 is a factor in the pathogenesis of X-linked hypophosphatemic rickets and osteomalacia and may modulate the phenotypic expression of this disease.

Full text

PDF
1020

Images in this article

1026Image
on p.1026
1028Image
on p.1028

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ANKER R. M. The determination of creatine and creatinine in urine; a correction factor for the determination of twenty-four-hour urinary excretion values. J Lab Clin Med. 1954 May;43(5):798–801. [PubMed] [Google Scholar]
  2. Arnaud C. D., Tsao H. S., Littledike T. Radioimmunoassay of human parathyroid hormone in serum. J Clin Invest. 1971 Jan;50(1):21–34. doi: 10.1172/JCI106476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. BURNETT C. H., DENT C. E., HARPER C., WARLAND B. J. VITAMIN D-RESISTANT RICKETS. ANALYSIS OF TWENTY-FOUR PEDIGREES WITH HEREDITARY AND SPORADIC CASES. Am J Med. 1964 Feb;36:222–232. doi: 10.1016/0002-9343(64)90085-3. [DOI] [PubMed] [Google Scholar]
  4. Balsan S., Garabedian M., Sorgniard R., Holick M. F., Deluca H. F. 1,25-dihydroxyvitamin D3 and 1, alpha-hydroxyvitamin D3 in children: biologic and therapeutic effects in nutritional rickets and different types of vitamin D resistance. Pediatr Res. 1975 Jul;9(7):586–593. doi: 10.1203/00006450-197507000-00007. [DOI] [PubMed] [Google Scholar]
  5. Baylink D., Wergedal J., Stauffer M. Formation, mineralization, and resorption of bone in hypophosphatemic rats. J Clin Invest. 1971 Dec;50(12):2519–2530. doi: 10.1172/JCI106752. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bijvoet O. L. Renal phosphate excretion in man. Folia Med Neerl. 1972;15(2):84–93. [PubMed] [Google Scholar]
  7. Birge S. J., Miller R. The role of phosphate in the action of vitamin D on the intestine. J Clin Invest. 1977 Nov;60(5):980–988. doi: 10.1172/JCI108878. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Brickman A. S., Coburn J. W., Kurokawa K., Bethune J. E., Harrison H. E., Norman A. W. Actions of 1,25-dihydroxycholecalciferol in patients with hypophosphatemic, vitamin-D-resistant rickets. N Engl J Med. 1973 Sep 6;289(10):495–498. doi: 10.1056/NEJM197309062891002. [DOI] [PubMed] [Google Scholar]
  9. Brooks M. H., Bell N. H., Love L., Stern P. H., Orfei E., Queener S. F., Hamstra A. J., DeLuca H. F. Vitamin-D-dependent rickets type II. Resistance of target organs to 1,25-dihydroxyvitamin D. N Engl J Med. 1978 May 4;298(18):996–999. doi: 10.1056/NEJM197805042981804. [DOI] [PubMed] [Google Scholar]
  10. Brumbaugh P. F., Haussler D. H., Bursac K. M., Haussler M. R. Filter assay for 1alpha, 25-dihydroxyvitamin D3. Utilization of the hormone's target tissue chromatin receptor. Biochemistry. 1974 Sep 24;13(20):4091–4097. doi: 10.1021/bi00717a005. [DOI] [PubMed] [Google Scholar]
  11. DRYER R. L., TAMMES A. R., ROUTH J. I. The determination of phosphorus and phosphatase with N-phenyl-p-phenylenediamine. J Biol Chem. 1957 Mar;225(1):177–183. [PubMed] [Google Scholar]
  12. DeLuca H. F. Vitamin D: the vitamin and the hormone. Fed Proc. 1974 Nov;33(11):2211–2219. [PubMed] [Google Scholar]
  13. Drezner M. K., Feinglos M. N. Osteomalacia due to 1alpha,25-dihydroxycholecalciferol deficiency. Association with a giant cell tumor of bone. J Clin Invest. 1977 Nov;60(5):1046–1053. doi: 10.1172/JCI108855. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. FROST H. H. Lamellar osteoid mineralized per day in man. Henry Ford Hosp Med Bull. 1960 Jun;8:267–272. [PubMed] [Google Scholar]
  15. Fischer J. A., Binswanger U., Dietrich F. M. Human parathyroid hormone. Immunological characterization of antibodies against a glandular extract and the synthetic amino-terminal fragments 1-12 and 1-34 and their use in the determination of immunoreactive hormone in human sera. J Clin Invest. 1974 Dec;54(6):1382–1394. doi: 10.1172/JCI107885. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Friedel R. O., Schanberg S. M. Incorporation in vivo of intracisternally injected 33 P i into phospholipids of rat brain. J Neurochem. 1971 Nov;18(11):2191–2200. doi: 10.1111/j.1471-4159.1971.tb05077.x. [DOI] [PubMed] [Google Scholar]
  17. Galante L., Colston K. W., Evans I. M., Byfield P. G., Matthews E. W., MacIntyre I. The regulation of vitamin D metabolism. Nature. 1973 Aug 17;244(5416):438–440. doi: 10.1038/244438a0. [DOI] [PubMed] [Google Scholar]
  18. Gertner J. M., Brenton D. B., Edwards R. H. 1alpha-hydroxyvitamin D3 in the treatment of nutritional and metabolic rickets and osteomalacia. Clin Endocrinol (Oxf) 1977 Dec;7 (Suppl):239s–244s. doi: 10.1111/j.1365-2265.1977.tb03388.x. [DOI] [PubMed] [Google Scholar]
  19. Glorieux F. H., Bordier P. J., Marie P., Delvin E. E., Travers R. Inadequate bone response to phosphate and vitamin D in familial hypophosphatemic rickets (FHR). Adv Exp Med Biol. 1978;103:227–232. doi: 10.1007/978-1-4684-7758-0_25. [DOI] [PubMed] [Google Scholar]
  20. Glorieux F. H., Holick M. F., Scriver C. R., DeLuca H. F. X-linked hypophosphataemic rickets: Inadequate therapeutic response to 1,25-dihydroxycholecalciferol. Lancet. 1973 Aug 11;2(7824):287–289. doi: 10.1016/s0140-6736(73)90793-9. [DOI] [PubMed] [Google Scholar]
  21. Glorieux F. H., Scriver C. R., Reade T. M., Goldman H., Roseborough A. Use of phosphate and vitamin D to prevent dwarfism and rickets in X-linked hypophosphatemia. N Engl J Med. 1972 Sep 7;287(10):481–487. doi: 10.1056/NEJM197209072871003. [DOI] [PubMed] [Google Scholar]
  22. Gray R. W., Wilz D. R., Caldas A. E., Lemann J., Jr The importance of phosphate in regulating plasma 1,25-(OH)2-vitamin D levels in humans: studies in healthy subjects in calcium-stone formers and in patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 1977 Aug;45(2):299–306. doi: 10.1210/jcem-45-2-299. [DOI] [PubMed] [Google Scholar]
  23. Haddad J. G., Chyu K. J. Competitive protein-binding radioassay for 25-hydroxycholecalciferol. J Clin Endocrinol Metab. 1971 Dec;33(6):992–995. doi: 10.1210/jcem-33-6-992. [DOI] [PubMed] [Google Scholar]
  24. Harrison H. E., Harrison H. C., Lifshitz F., Johnson A. D. Growth disturbance in hereditary hypophosphatemia. Am J Dis Child. 1966 Oct;112(4):290–297. doi: 10.1001/archpedi.1966.02090130064005. [DOI] [PubMed] [Google Scholar]
  25. Haussler M., Hughes M., Baylink D., Littledike E. T., Cork D., Pitt M. Influence of phosphate depletion on the biosynthesis and circulating level of 1alpha,25-dihydroxyvitamin D. Adv Exp Med Biol. 1977;81:233–250. doi: 10.1007/978-1-4613-4217-5_24. [DOI] [PubMed] [Google Scholar]
  26. Hawker C. D. Parathyroid hormone: radioimmunoassay and clinical interpretation. Ann Clin Lab Sci. 1975 Sep-Oct;5(5):383–398. [PubMed] [Google Scholar]
  27. Hughes M. R., Baylink D. J., Jones P. G., Haussler M. R. Radioligand receptor assay for 25-hydroxyvitamin D2/D3 and 1 alpha, 25-dihydroxyvitamin D2/D3. J Clin Invest. 1976 Jul;58(1):61–70. doi: 10.1172/JCI108459. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Hughes M. R., Brumbaugh P. F., Hussler M. R., Wergedal J. E., Baylink D. J. Regulation of serum 1alpha,25-dihydroxyvitamin D3 by calcium and phosphate in the rat. Science. 1975 Nov 7;190(4214):578–580. doi: 10.1126/science.1188357. [DOI] [PubMed] [Google Scholar]
  29. JACKSON W. P., DOWDLE E., LINDER G. C. Vitamin-D-resistant ostemalacia. Br Med J. 1958 May 31;1(5082):1269–1274. doi: 10.1136/bmj.1.5082.1269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Kleerekoper M., Coffey R., Creco T., Nichols S., Cooke N., Murphy W., Avioli L. V. Hypercalcemic hyperparathyroidism in hypophosphatemic rickets. J Clin Endocrinol Metab. 1977 Jul;45(1):86–94. doi: 10.1210/jcem-45-1-86. [DOI] [PubMed] [Google Scholar]
  31. Marx S. J., Spiegel A. M., Brown E. M., Gardner D. G., Downs R. W., Jr, Attie M., Hamstra A. J., DeLuca H. F. A familial syndrome of decrease in sensitivity to 1,25-dihydroxyvitamin D. J Clin Endocrinol Metab. 1978 Dec;47(6):1303–1310. doi: 10.1210/jcem-47-6-1303. [DOI] [PubMed] [Google Scholar]
  32. McNair S. L., Stickler G. B. Growth in familial hypophosphatemic vitamin-D-resistant rickets. N Engl J Med. 1969 Sep 4;281(10):512–516. doi: 10.1056/NEJM196909042811001. [DOI] [PubMed] [Google Scholar]
  33. Mellits E. D., Dorst J. P., Cheek D. B. Bone age: its contribution to the prediction of maturational or biological age. Am J Phys Anthropol. 1971 Nov;35(3):381–384. doi: 10.1002/ajpa.1330350314. [DOI] [PubMed] [Google Scholar]
  34. Merz W. A., Schenk R. K. Quantitative structural analysis of human cancellous bone. Acta Anat (Basel) 1970;75(1):54–66. doi: 10.1159/000143440. [DOI] [PubMed] [Google Scholar]
  35. Morgan J. M., Hawley W. L., Chenoweth A. I., Retan W. J., Diethelm A. G. Renal transplantation in hypophosphatemia with vitamin D-resistant rickets. Arch Intern Med. 1974 Sep;134(3):549–552. [PubMed] [Google Scholar]
  36. Omdahl J. L., DeLuca H. F. Regulation of vitamin D metabolism and function. Physiol Rev. 1973 Apr;53(2):327–372. doi: 10.1152/physrev.1973.53.2.327. [DOI] [PubMed] [Google Scholar]
  37. PIERCE D. S., WALLACE W. M., HERNDON C. H. LONG-TERM TREATMENT OF VITAMIN-D RESISTANT RICKETS. J Bone Joint Surg Am. 1964 Jul;46:978–997. [PubMed] [Google Scholar]
  38. Peacock M., Heyburn P. J., Aaron J. E. Vitamin D resistant hypophosphataemic osteomalacia: treatment with 1alpha-hydroxyvitamin D3. Clin Endocrinol (Oxf) 1977 Dec;7 (Suppl):231s–237s. doi: 10.1111/j.1365-2265.1977.tb03387.x. [DOI] [PubMed] [Google Scholar]
  39. Russell R. G., Smith R., Preston C., Walton R. J., Woods C. G., Henderson R. G., Norman A. W. The effect of 1,25-dihydroxycholecalciferol on renal tubular reabsorption of phosphate, intestinal absorption of calcium and bone histology in hypophosphataemic renal tubular rickets. Clin Sci Mol Med. 1975 Mar;48(3):177–186. doi: 10.1042/cs0480177. [DOI] [PubMed] [Google Scholar]
  40. STAMP W. G., WHITESIDES T. E., FIELD M. H., SCHEER G. E. TREATMENT OF VITAMIN-D RESISTANT RICKETS. A LONG-TERM EVALUATION OF ITS EFFECTIVENESS. J Bone Joint Surg Am. 1964 Jul;46:965–977. [PubMed] [Google Scholar]
  41. Scriver C. R., Reade T. M., DeLuca H. F., Hamstra A. J. Serum 1,25-dihydroxyvitamin D levels in normal subjects and in patients with hereditary rickets or bone disease. N Engl J Med. 1978 Nov 2;299(18):976–979. doi: 10.1056/NEJM197811022991803. [DOI] [PubMed] [Google Scholar]
  42. Scriver C. R. Rickets and the pathogenesis of impaired tubular transport of phosphate and other solutes. Am J Med. 1974 Jul;57(1):43–49. doi: 10.1016/0002-9343(74)90766-9. [DOI] [PubMed] [Google Scholar]
  43. Stickler G. B., Beabout J. W., Riggs B. L. Vitamin D-resistant rickets: clinical experience with 41 typical familial hypophosphatemic patients and 2 atypical nonfamilial cases. Mayo Clin Proc. 1970 Mar;45(3):197–218. [PubMed] [Google Scholar]
  44. Stickler G. B., Hayles A. B., Rosevear J. W. Familial hypophosphatemic vitamin D resistant rickets: effect of increased oral calcium and phosphorus intake without high doses of vitamin D. Am J Dis Child. 1965 Dec;110(6):664–667. doi: 10.1001/archpedi.1965.02090030692013. [DOI] [PubMed] [Google Scholar]
  45. TAPIA J., STEARNS G., PONSETI I. V. VITAMIN-D RESISTANT RICKETS. A LONG-TERM CLINICAL STUDY OF 11 PATIENTS. J Bone Joint Surg Am. 1964 Jul;46:935–958. [PubMed] [Google Scholar]
  46. Tenenhouse H. S., Scriver C. R., McInnes R. R., Glorieux F. H. Renal handling of phosphate in vivo and in vitro by the X-linked hypophosphatemic male mouse: evidence for a defect in the brush border membrane. Kidney Int. 1978 Sep;14(3):236–244. doi: 10.1038/ki.1978.115. [DOI] [PubMed] [Google Scholar]
  47. WILSON D. R., YORK S. E., JAWORSKI Z. F., YENDT E. R. STUDIES IN HYPOPHOSPHATEMIC VITAMIN D-REFRACTORY OSTEOMALACIA IN ADULTS. Medicine (Baltimore) 1965 Mar;44:99–134. doi: 10.1097/00005792-196503000-00001. [DOI] [PubMed] [Google Scholar]
  48. WINTERS R. W., GRAHAM J. B., WILLIAMS T. F., McFALLS V. W., BURNETT C. H. A genetic study of familial hypophosphatemia and vitamin D resistant rickets. Trans Assoc Am Physicians. 1957;70:234–242. [PubMed] [Google Scholar]
  49. Walton R. J., Bijvoet O. L. Nomogram for derivation of renal threshold phosphate concentration. Lancet. 1975 Aug 16;2(7929):309–310. doi: 10.1016/s0140-6736(75)92736-1. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES